Obesity is one of the biggest health threats to modern people, but drugs used for weight loss in the past are often withdrawn due to serious side effects or ineffectiveness; but a diabetes drug that has just been approved for registration in the United States may become a new generation of weight loss saviors , related research has been published in the “New England Journal of Medicine”.
Participants are obese
The clinical study involved 2,539 obese individuals with an average weight of 231 pounds and an average BMI of 38 who did not have diabetes but had at least one other obesity-related disorder such as hypertension, dyslipidemia, sleep apnea or cardiovascular disease , and have tried dieting and losing weight one or more times. All were randomly assigned to one of four groups, three different doses of the new hypoglycemic drug or a placebo.
Significant weight loss
The results showed that all three different doses of the new antidiabetic drug had significant weight loss effects compared to placebo, with the medication group losing an average of 49 pounds after completing 72 weeks of treatment, with participants on the highest dose losing an average of 49 pounds. Lost 20% of the body weight and lost an average of 52 pounds, and the lowest dose group also lost an average of 15% of the body weight, about 35 pounds; more importantly, the cardiometabolic indicators of the three drug groups improved. The placebo group lost an average of only 5 pounds.
Effectively regulate blood sugar
The new hypoglycemic agent is a dual incretin (GLP-1 and GIP) agonist. After the human body uses it, it will release incretin, thereby stimulating insulin secretion and inhibiting glucagon, so as to achieve the effect of regulating blood sugar. Studies have shown that common side effects of the drug include nausea, diarrhea and constipation.
Originally published on AM730 https://www.am730.com.hk/health/new hypoglycemic drug as weight loss savior-study-52lbs lost in 72 weeks/323385